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Abstract. 6,9-Disubstituted purines and 7-deazapurines are known to be powerful inhibitors of 
Mycobacterium tuberculosis (Mtb) in vitro. Analogs modified in the 6-membered ring 
(imidazopyridines, pyrrolopyridines, benzimidazoles and indoles) were synthesized and evaluated 
as Mtb inhibitors. The targets were prepared by functionalization on the bicyclic heterocycle or 
from simple pyridines. The results reported herein, indicate that the purine N-1, but not N-3, is 
important for binding to the unknown target. The 3-deazapurines appears to be slightly more active 
compared to the parent purines and slightly less active than their 7-deazapurine isomers. Removal 
of both the purine N-3 and N-7 did not result in further enhanced antimycobacterial activity but the 
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toxicity towards mammalian cells was increased. Both 3-deaza and 3,7-dideazapurines exhibited a 
modest activity against of the Mtb isolate in the state of non-replicating persistence. 
 
Introduction 
Tuberculosis (TB) claims approximately 2 million deaths pr. year worldwide and resistance to the 
drugs in use is a growing problem. Also agents that reduce the duration and complexity of the 
current therapy would have a major impact on the overall cure rate.
1
 We have studied 6,9-
disubstituted purines as potent inhibitors of Mycobacterium tuberculosis (Mtb) in vitro, for instance 
compounds 1a and 1b (Fig. 1).
2
 Lately we have examined several classes of non-purine analogs, 
and identified the 7-deazapurines 1c and 1d as even more active antimycobacterials.
3e
 These 
compounds are highly selective towards Mtb compared to other microorganisms, active against 
several drug resistant strains of Mtb, generally non-toxic towards mammalian cells, and able to 
affect Mtb inside macrophages.
2,3
 We now report the synthesis and antimycobacterial activities for 
purine- or 7-deazapurine analogs modified in the 6-membered ring (general structure, see Fig. 1). 
(Fig. 1) 
The synthesis of 1-deazapurines 5 is shown in Scheme 1. 2-Chloropyridines 2
4 
were reacted with p-
methoxybenzylamine to give compounds 3 in high yields. The reaction on the 2,6-dichloropyridine 
3b was highly regioselective and only minor amounts of the other possible regioisomer were 
observed. The nitropyridines 3 were efficiently reduced to diamines 4 and the latter were reacted 
with triethylorthoformate to give the targets 5. 
(Scheme 1) 
The 3-deazapurine 7 was readily available by a Stille coupling to introduce the furyl substituent on 
the previously known structure 6
5
 as shown in Scheme 2. 
(Scheme 2) 
For the chlorinated 3-deazapurine 12 the pyridine 8
6
 was chosen as the starting point (Scheme 3). 
The amine 8 was N-alkylated with p-methoxybenzyl chloride, and the furyl group was introduced 
by a highly regioselective Stille coupling, where only formation of a small amount of the difuryl 
analog was observed. The lasts steps follows those used in the synthesis of the 1-deazapurines 5 
(Scheme 1); reduction of the nitro group followed by reaction of the diamine with 
triethylortoformate to give the bicycle 12. The regioselective outcome of the Stille coupling was 
determined by NOE spectroscopy on the diamine 11 as shown in Scheme 3. 
(Scheme 3) 
The bicyclic compounds 13 and 14 were attractive starting materials for the synthesis of the 1,7-
dideaza- 17 and 3,7-dideazapurines 18, since compounds 13a, 14a, and 14b were commercially 
available (Scheme 4). Targets 17 and 18 were synthesized by N-alkylation of the pyrrole nitrogen 
followed by Pd-catalyzed cross coupling to introduce the furyl substituent. The 1,7-dideazapurine 
15a was not reactive under conventional Stille coupling conditions, but the target 17a was isolated 
in an excellent yield when a Suzuki coupling employing the reactive catalyst [(t-Bu)3P]2Pd was 
performed. The analog of compound 15b where Y = Cl (structure not shown) was essentially 
unreactive under both Stille and Suzuki coupling conditions, but the bromide 15b, synthesized by 
alkylation of 13b,
7
 could very easily be converted to the furane 17 by a Stille coupling. The reaction 
was carried out at ambient temperature to avoid exchange of both halides. The target 18b was 
synthesized from compound 16b by a Stille coupling. The regioselectivity was complete, and 
proved by the selective NOE shown in Scheme 4 as well as by HMBC NMR spectroscopy. The 
conversion was moderate and 33% of the starting material 16b was recovered. 
(Scheme 4) 
The benzimidazole 22 was synthesized from the commercially available nitrobenzene 19 (Scheme 
5). The nitro group was conveniently reduced and the diamine 20 gave the benzimidazole 21 upon 
reaction with triethylorthoformate, but in contrast to similar reactions on the diaminopyridines 4 
(Scheme 1) and 11 (Scheme 3). When the ring forming reaction was performed with 
triethylorthoformate and acetic acid anhydride, the product 21 was contaminated with ca 20% of the 
corresponding 3-metylbenzimidazole (structure not shown). Instead the cyclization was carried out 
in the presence of p-toluenesulfonic acid.
8 
Low reactivity of bromobenzimidazoles in Pd-catalyzed 
cross couplings is reported before,
9
 and the final Stille coupling to give the target 22 required a 
reactive catalyst; [(t-Bu)3P]2Pd. 
(Scheme 5) 
Finally the indole 25, formally the 1,3,7-trideaza analog of the purine 1a (Fig. 1) was synthesized 
by N-alkylation followed by Stille coupling, from the bromoindole 23. Dialkylation of indoles is 
not uncommon,
10
 and also compound 24b was formed in the alkylation step. Due to the inactivity of 
the indole 25 as Mtb inhibitor (see below), no attempt was done to improve the outcome of the 
alkylation reaction. 
(Scheme 6) 
Biological evaluation 
The target compounds 5a, 5b, 7, 12, 17a, 17b, 18a, 18b, 22 and 24 were screened for activity 
against M. tuberculosis H37Rv in the microplate alamar blue assay (MABA)
11
 and the MIC values 
are given in Table 1. For compounds displaying substantial activity, cytotoxicity towards 
mammalian cells (VERO cells) was also examined. The values for the previously synthesized 
purines and deazapurines 1a – d as well as a general structure of the targets, are shown in Fig. 1. 
The 1-deazapurines 5a and 5b and the 1,7-dideazapurines 17a and 17b possessed no significant 
inhibitory activity against Mtb, indicating that a nitrogen in the purine 1-possition may be important 
for binding to the (unknown) target. In contrast to earlier findings studying purines,
2
 7-
deazapurine
3e
 or pyrimidine
3b,3d
 analogs as antimycobacterials, it is also interesting to note that this 
is the first time we observe that a chlorine, in what may be referred to as the 2-position in the parent 
purine, does not increase the antimycobacterial activity. The 3-deazapurines 7 and 12, on the other 
hand, where slightly more active than the parent purines (compounds 1a and 1b, respectively), 
indicating that the purine N-3 is not involved in binding to target. The toxicity towards mammalian 
cells (EC50 VERO cells >128 M) was also low for these compounds. In compounds 18 both the 
purine N-3 and N-7 is changed with CH. These modifications did not result in an additional 
improvement of the activity compared to the corresponding 7-deaza- (1c and 1d), but the activity is 
slightly increased compared to the 3-deazapurines 7 and 12. Furthermore, the toxicity towards 
VERO cells was increased substantially when the N-7 nitrogen was removed. This is in accordance 
with what we found when we were comparing purines 1a and 1b with the deazapurines 1c and 1d.
3e
 
The benzimidazole 22 and the indole 25 did not exhibit significant antimycobacterial activity 
compared with the most active compounds in this series. The results presented herein and in our 
recent paper on 7- and 9-deazapurines
3e
 indicate that the purine N-1 and N-9, but not N-3 and N-7, 
are important for binding to the elusive target. However, it must be stressed that the changes in 
antimycobacterial activities observed may also be a result of different uptake or metabolism by the 
Mtb cells. 
A sub-population of the Mtb isolate in a state of non-replicating persistence (NRP). NRP is 
considered to be an important factor contributing to the long treatment duration (≥6 months 
required). Hence we investigated if the antimycobacterial purines and non-purine analogs described 
herein also could affect Mtb in NRP. Compounds 7, 12, and 18 were thus tested in the low-oxygen-
recovery assay (LORA)
12
 (Table 1). These substances (except 18b) were all more active in the 
LORA assay than the purines and 7-deazapurines (MIC LORA >128 M for all compounds 1a-d). 
3e 
Unfortunately the activities found are still quite moderate. The most potent compound in the 
LORA assay, the 3,7-dideazapurine 18a, is unfortunately exhibiting the highest toxicity towards 
VERO cells among the compounds tested for mammalian cytotoxicity. 
Compounds 5a, 5b, 7, 12, 17a, 17b, 18a, 18b, 22 and 25 displayed no significant activities against 
Staphylococcus aureus and Escherichia coli. The MICs for all compounds were >16 g/mL against 
both bacteria. There was no visible difference in the growth responses of the quality control (QC) 
strains across the range of dilutions tested. The MICgentamicin value for the quality control strains of 
S. aureus and E. coli was 0.5 µg/mL which is within the acceptable specified range.
13
 This points 
towards a selective antimycobacterial mechanism for the 3-deazapurines 7, 12 and 18 as previously 
found also for purines
2
 and 7-deazapurines.
3e
   
(Table 1) 
 
Experimental 
The 
1
H NMR spectra were recorded at 600 MHz with a Bruker AVII 600 instrument, at 300 MHz 
with a Bruker Avance DPX 300 instrument, or at 200 MHz with a Varian Gemini instrument. The 
decoupled 
13
C NMR spectra were recorded at 150, 125, 75 or 50 MHz using instruments mentioned 
above. Mass spectra under electron impact conditions were recorded with a VG Prospec instrument 
at 70 eV ionizing voltage, and are presented as m/z (% rel. int.). Elemental analyses were performed 
at School of Chemistry, University of Birmingham, UK. Melting points were determined with a 
Büchi Melting Point B-545 apparatus and are uncorrected. Triethylamine was distilled from CaH2 
and stored over molecular sieves (3 Å). Dioxane was distilled from Na/benzophenone, n-butanol 
from BaO and acetic acid anhydride from CaCl2. Dry THF and DMF were obtained from a solvent 
purification system, MB SPS-800 from MBraun, Garching, Germany. Silica gel for flash 
chromatography was purchased from Merck, Darmstadt, Germany (Merck No. 09385). All other 
reagents were commercially available and used as received. 4-Chloro-7-azaindole (13a) was 
purchased from Carbocore Research Chemicals and Intermediates, The Woodlands, USA; 4-chloro-
1H-pyrrolo[3,2-c]pyridine (14a) from CreaGen Biosciences Inc, Woburn, USA; 4,6-dichloro-1H-
pyrrolo[3,2-c]pyridine (14b) from Activate Scientific GmbH, Prien, Germany and 3-bromo-N-(4-
methoxybenzyl)-2-nitroaniline (19) from Combi-Blocks, LLC, San Diego, USA. Compounds 
synthesized by literature procedures: 2a,
4
 2b,
4
 6,
5
 and 8.
6
 4-Bromo-6-chloro-1H-pyrrolo[2,3-
b]pyridine 13b was also synthesized according to the litterature
7
 and isolated as an inseparable 
mixture (77 : 23) of 13b and the 4,6-dichloro analog. Activities against Mtb H37Rv (ATCC #27294) 
(MABA and LORA assay),
3e,11,12
 and VERO cells
2
 were determined as reported before. 
4-(Furan-2-yl)-N-(4-methoxybenzyl)-3-nitropyridin-2-amine (3a). A mixture of compound 2a 
(350 mg, ca 88% pure, ca. 1.38 mmol), 4-methoxybenzylamine (0.400 mL, 3.12 mmol) and 
triethylamine (0.430 mL, 3.12 mmol) in n-butanol (10 mL) was heated at 100 
o
C for 18 h under N2 
and evaporated in vacuo. The residue was diluted with CH2Cl2 (ca. 10 mL) and evaporated with 
small amount of silica gel. The product was purified by flash chromatography on silica gel eluting 
with hexane followed by EtOAc-hexane (1:5) and finally EtOAc-hexane (1:4); yield 435 mg (97%), 
mp 119-120 
o
C, yellow solid. 
1
H NMR (Me2CO-d6, 300 MHz)  3.75 (s, 3H, CH3), 4.70 (d, J = 5.8 
Hz, 2H, CH2), 6.73 (dd, J = 3.5 and 1.7 Hz, 1H, H-4 in furyl), 6.86 (d, J = 8.7 Hz, 2H, Ar), 6.93-
6.96 (m, 3H, NH, H-5 and H-3 in furyl), 7.32 (d, J =8.8 Hz, 2H, Ar), 7.73 (dd, J = 1.8 and 0.7 Hz, 
H-5 in furyl), 8.25 (d, J = 5.1 Hz, H-6); 
13
C NMR (Me2CO-d6, 75 MHz)  44.9 (CH2), 55.4 (CH3), 
110.8 (C-5), 112.8 (C-2 in furyl), 113.1 (C-4 in furyl), 114.5 (CH in Ar), 129.3 (C-3), 129.7 (CH in 
Ar), 132.5 (C-4 / C-1 in Ar), 132.8(C-4 / C-1 in Ar), 146.1 (C-5 in furyl), 148.6 (C-2 in furyl), 
151.4 (C-2), 151.8 (C-6), 159.8 (C-4 in Ar); MS EI m/z (rel. %) 325 (12, M
+
), 308 (95), 277 (100), 
189 (30), 145 (24), 121 (70); HRMS Found 325.1063, calcd. for C17H15N3O4 325.1063.  
6-Chloro-4-(furan-2-yl)-N-(4-methoxybenzyl)-3-nitropyridin-2-amine (3b). A mixture of 
compound 2b (300 mg, 1.16 mmol), 4-methoxybenzylamine (0.08 mL, 0.6 mmol) and 
triethylamine (0.08 mL, 0.6 mmol) in DMF (10 mL) was stirred under N2 at ambient temperature 
for 24 h and poured in to water (100 mL). The resulting mixture was extracted with EtOAc (2  50 
mL), the combined organic extracts were washed with brine (50 mL), dried (MgSO4) and 
evaporated in vacuo. The residue was diluted with CH2Cl2 (ca. 20 mL) and evaporated with small 
amount of silica gel. The product was purified by flash chromatography on silica gel eluting with 
hexane followed by CH2Cl2-hexane (1:4) and finally CH2Cl2-hexane (1:2); yield 183 mg (88%), 
yellow wax. 
1
H NMR (MeCN-d3, 300 MHz)  3.75 (s, 1H, OCH3), 4.57 (d, J = 5.8 Hz, 2H, CH2), 
6.59 (dd, J = 3.4 and 1.7 Hz, 1H, H-4 in furyl), 6.85-6.88 (m, 3H, H-5 and CH in Ar), 6.92 (br d, J 
= 3.5 Hz, 1H, H- 3 in furyl), 7.00 (br s, 1H, NH), 7.28 (d, J = 8.6 Hz, 2H, CH in Ar), 7.62 (br d, J = 
0.9 Hz, 1H, H-5 in furyl); 
13
C NMR (MeCN-d3, 75 MHz)  45.0 (CH2), 55.8 (OCH3), 110.6 (C-5), 
113.3 (C-4 in furyl), 113.9 (C-3 in furyl), 114.7 (CH in Ar), 127.6 (C-3), 129.8 (CH in Ar), 131.7 
(C-1 in Ar), 136.5 (C-6), 146.5 (C-5 in furyl), 147.9 (C-2 in furyl), 151.7 (C-2), 152.9 (C-6), 159.9 
(C-4 in Ar), the signal from C-4 was hidden; MS EI m/z (rel. %) 359 (1, M
+
), 344 (18), 311 (44), 
223 (15), 179 (19), 121 (100), 77 (12); HRMS Found 359.0663, calcd. for C17H14ClN3O4 359.0673. 
4-(Furan-2-yl)-N
2
-(4-methoxybenzyl)pyridine-2,3-diamine (4a). Na2S2O4 (125 mg, 0.740 mmol) 
was added to a well-stirred suspension of compound 3a (60 mg, 0.18 mmol) and K2CO3 (124 mg, 
0.900 mmol) in MeOH (3.00 mL) and water (0.50 mL) under N2 The resulting mixture was stirred 
at ambient temperature for 12 h and evaporated in vacuo. CH2Cl2 (10 mL) was added and the 
resulting suspension was filtered through a cotton plug. The filtrate was dried (MgSO4) and 
evaporated in vacuo. The product was purified by flash chromatography on silica gel eluting with 
hexane followed by EtOAc-hexane (1:5); yield 50 mg (94%), pale yellow wax. 
1
H NMR (MeCN-
d3, 300 MHz)  3.75 (s, 3H, CH3), (br s, 2H, NH2), 4.55 (d, J = 5.7 Hz, 2H, CH2), (br s, 1H, NH), 
6.58 (dd, J = 3.5 and 1.8 Hz, 1H, H-4 in furyl), 6.72-6.76 (m, 2H, H-5 and H-3 in furyl), 6.86 (d, J = 
8.7 Hz, 2H, Ar), 7.30 (d, J = 8.8 Hz, 2H, Ar), 7.50 (d, J = 5.4 Hz, H-6), 7.62 (dd, J = 1.8 and 0.6 
Hz, H-5 in furyl); 
13
C NMR (MeCN-d3, 75 MHz)  45.4 (CH2), 55.7 (CH3), 109.2 (C-3 in furyl), 
111.2 (C-5), 112.4 (C-4 in furyl), 114.5 (CH in Ar), 120.1 (C-4), 126.3 (C-3), 129.7 (CH in Ar), 
133.7 (C-1 in Ar), 137.0 (C-6), 143.4 (C-5 in furyl), 150.6 (C-2), 153.0 (C-2 in furyl), 159.5 (C-4 in 
Ar); MS EI m/z (rel. %) 295 (57, M
+
), 136 (6), 121 (100), 78 (5), 77 (6); HRMS Found 295.1320, 
calcd. for C17H17N3O2 295.1321.  
6-Chloro-4-(furan-2-yl)-N
2
-(4-methoxybenzyl)pyridine-2,3-diamine (4b). Raney Ni (ca. 100 
mg, washed with methanol) was added to a solution of compound 3b (165mg, 0.46 mmol) in 
MeOH (10 mL) at 0 
o
C, before NaBH4 (35 mg, 0.92 mmol) was added. The resulting mixture was 
stirred at 0 
o
C for 10 min and at ambient temperature for 10 min in an open flask. The reaction 
mixture was filtered through a small celite pad, and the filtrate was evaporated in vacuo. The 
residue was dissolved in EtOAc (20 mL), washed with water (20 mL) and brine (10 mL), dried 
(MgSO4) and evaporated in vacuo. The product was purified by flash chromatography on silica gel 
eluting with hexane followed by EtOAc-hexane (1:4) and finally EtOAc-hexane (2:3); yield 135 mg 
(89%), pale yellow wax. 
1
H NMR (DMSO-d6, 300 MHz)  3.71 (s, 1H, OCH3), 4.46 (d, J = 5.3 Hz, 
2H, CH2), 5.16 (s, 2H, NH2), 6.64 (dd, J = 3.4 and 1.8 Hz, 1H, H-4 in furyl), 6.70 (s, 1H, H-5), 6.76 
(t, J = 5.4 Hz, 1H, NH), 6.88 (d, J = 8.6 Hz, 2H, CH in Ar), 6.98 (d, J = 3.4 Hz, 1H, H-3 in furyl), 
7.28 (d, J = 8.5 Hz, 2H, CH in Ar), 7.79 (br d, J = 1.3 Hz, 1H, H-5 in furyl); 
13
C NMR (DMSO-d6, 
75 MHz)  40.3 (CH2), 55.0 (OCH3), 106.8 (C-5), 109.2 (C-3 in furyl), 111.8 (C-4 in furyl), 113.6 
(CH in Ar), 119.3 (C-4), 124.2 (C-3), 128.9 (CH in Ar), 131.9 (C-1 in Ar), 135.0 (C-6), 142.8 (C-5 
in furyl), 148.4 (C-2), 150.2 (C-2 in furyl), 158.2 (C-4 in Ar); MS EI m/z (rel. %) 331 / 329 (8 / 23, 
M
+
), 208 (2), 122 (16), 121 (100), 77 (6); HRMS Found 329.0929, calcd. for C17H16ClN3O2 
329.0931.  
7-(Furan-2-yl)-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridine (5a). A mixture of compound 4 
(150 mg, 0.510 mmol) in triethylorthoformate (2.0 mL) and acetic anhydride (2.0 mL) was heated 
at reflux under N2 for 1.5 h and evaporated in vacuo. The product was purified by flash 
chromatography on silica gel eluting with hexane followed by EtOAc-hexane (1:5) and finally 
EtOAc-hexane (1:4); yield 140 mg (90%), mp 105-107
 o
C, colorless solid. 
1
H NMR (CDCl3, 300 
MHz)  3.76 (s, 3H, CH3), 5.41 (s, 2H, CH2), 6.60 (dd, J = 3.4 and 1.8 Hz, 1H, H-4 in furyl), 6.85 
(d, J = 8.7 Hz, 2H, Ar ), 7.25 (d, J = 8.7 Hz, 2H, Ar), 7.56-7.60 (m, 2H, H-6 and H-5 in furyl), 7.66 
(d, J = 3.5 Hz, 1H, H-3 in furyl), 8.01 (s, 1H, H-2), 8.41 (d, J = 5.1 Hz, H-5); 
13
C NMR (CDCl3, 75 
MHz)  46.8 (CH2), 55.3 (CH3), 112.4 (C-6 / C-4 in furyl), 112.5 (C-6 / C-4 in furyl), 114.2 (C-3 in 
furyl), 114.4 (CH in Ar), 127.7 (C-1 in Ar), 129.0 (C-7), 129.3 (CH in Ar), 129.7 (C-7a), 143.3 (C-
2), 143.7 (C-5 in furyl), 144.7 (C-5), 147.5 (C-3a), 149.2 (C-2 in furyl), 159.6 (C-4 in Ar); MS EI 
m/z (rel. %)  305 (87, M
+
), 290 (15), 153 (6), 121 (100), 77 (7); HRMS Found 305.1164, calcd. for 
C18H15N3O2 305.1164. Anal. Found C, 71.00; H, 4.96; N, 13.72. C18H15N3O2 requires C, 70.81; H, 
4.95; N, 13.76%.  
5-Chloro-7-(furan-2-yl)-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridine (5b). A mixture of 
compound 4b (120 mg, 0.510 mmol) in triethylorthoformate (2.0 mL) and acetic anhydride (2.0 
mL) was heated at reflux under N2 for 1.5 h and evaporated in vacuo. The product was purified by 
flash chromatography on silica gel eluting with hexane followed by EtOAc-hexane (1:4) and finally 
EtOAc-hexane (2:3); yield 102 mg (83%), mp 121-122
 o
C, colorless crystals. 
1
H NMR (MeCN-d3, 
300 MHz)  3.74 (s, 1H, OCH3), 5.35 (s, 2H, CH2), 6.68 (dd, J = 3.4 and 1.8 Hz, 1H, H-4 in furyl), 
6.88 (d, J = 8.7 Hz, 2H, CH in Ar), 7.53 (s, 1H, H-6), 7.72-7.75 (m, 2H, H-5 and H-3 in furyl), 8.21 
(s, 1H, H-2); 
13
C NMR (MeCN-d3, 75 MHz)  47.4 (CH2), 55.8 (OCH3), 112.2 (C-6), 113.7 (C-4 in 
furyl), 115.0 (CH in Ar), 116.4 (C-3 in furyl), 129.3 (C-1 in Ar), 130.0 ( C-7a), 130.1 (CH in Ar), 
131.7 (C-7), 145.6 (C-2 / C-5 in furyl), 145.7 (C-2 / C-5 in furyl), 146.5 (C-5), 147.9 (C-3a), 149.2 
(C-2 in furyl), 160.4 (C-4 in Ar); MS EI m/z (rel. %) 341 / 339 (17 / 40, M
+
), 122 (16), 121 (100), 
78 (8), 77 (8); HRMS Found 339.0775, calcd. for C18H14ClN3O2 339.0775. Anal. Found C, 63.58; 
H, 3.85; N, 12.37. C18H14ClN3O2 requires C, 63.63; H, 4.15 ; N, 12.37%. 
4-(Furan-2-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridine (7). A mixture of compound 6 
(100 mg, 0.370 mmol), Pd(dppf)Cl2 (15 mg, 0.019 mmol) and 2-furyl(tributyl)tin (0.14 mL, 0.44 
mmol) in DMF (4 mL) was stirred at 90 
o
C under N2 for 18 h, and evaporated in vacuo. KF in 
MeOH (sat. sol., 10 mL) was added to the residue and the mixture stirred for 24 h. The solvent was 
evaporated with small amount of silica. The product was purified by flash chromatography on silica 
gel eluting with hexane followed by EtOAc-hexane (1:2); yield 66 mg (60%), mp 126-128
o 
C, pale 
yellow solid.
 1
H NMR (CDCl3, 300 MHz)  3.77 (s, 3H, OCH3), 5.28 (s, 2H, CH2), 6.60 (dd, J = 3.4 
and 1.8 Hz, 1H, H-4 in furyl), 6.85 (d, J = 8.7 Hz, 2H, Ar), 7.10 (d, J = 8.3 Hz, 2H, Ar), 7.10 (d, J = 
5.7 Hz, 1H, H-7), 7.66 (dd, 1H, J = 0.8 and 1.7 Hz, H-5 in furyl), 7.72 (dd, 1H, J = 0.7 and 3.4 Hz 
H-5 in furyl); 
13
C NMR (CDCl3, 75 MHz)  48.7 (CH2), 55.3 (OCH3), 104.2 (C-7), 112.0 (C-4 in 
furyl), 113.7 (C-3 in furyl), 114.6 (CH in Ar), 126.4 (C-1 in Ar), 128.7 (CH in Ar), 136.5 (C-3a), 
139.5 (C-7a), 141.5 (C-4), 141.9 (C-6), 144.0 (C-2 and C-5 in furyl), 151.1 (C-2 in furyl), 159.8 (C-
4 in Ar); MS EI m/z (rel. %)  305 (43, M
+
), 122 (9), 121 (100), 77 (5); HRMS Found 305.1164, 
calcd. for C18H15N3O2 305.1164. Anal. Found C, 70.89; H, 4.86; N, 13.58. C18H15N3O2 requires C, 
70.81; H, 4.95; N, 13.76%. 
2,6-Dichloro-N-(4-methoxybenzyl)-3-nitropyridin-4-amine (9). NaH (69 mg, ca 60%, ca. 1.73 
mmol) was suspended in THF (4 mL) at 0 
o
C and a solution of compound 8 (300 mg, 1.44 mmol) in 
THF (4 mL) was added dropwise under N2 The resulting red mixture was stirred at 0 
o
C for 1 h. In 
another flask containing NaI (259 mg, 1.73 mmol) in THF (4 mL), was added 4-methoxybenzyl 
chloride (0.23 mL, 1.7 mmol) and the resulting suspension was stirred at ambient temperature under 
N2 for 1 h. The benzyl halide suspension was slowly added to the compound 8 containing solution 
at 0 
o
C. The resulting mixture was stirred at 0 
o
C for 2 h, the ice bath was removed and the reaction 
was allowed to stir at ambient temperature for 14 h before the reaction mixture was poured on to 
ice-water (ca. 100 mL) and extracted with EtOAc (2  70 mL). The combined organic layers were 
washed with brine (50 mL), dried (MgSO4) and evaporated in vacuo. The product was purified by 
flash chromatography on silica gel eluting with hexane followed by EtOAc-hexane (1:5); yield 330 
mg (69%), yellow wax.
 1
H NMR (DMSO-d6, 300 MHz)  3.72 (s, 3H, CH3), 4.43 (d, J = 6.0 Hz, 
2H, CH2), 6.89-6.93 (m, 3H, H-5 and 2H in Ar), 7.25 (d, J = 8.7 Hz, 2H, Ar), 8.29 (t, J = 6.0 Hz, 
1H, NH); 
13
C NMR (DMSO-d6, 75 MHz)  44.9 (CH2), 55.0 (CH3), 106.9 (C-5), 114.0 (CH in Ar), 
128.3 (CH in Ar), 128.8 (C-1 in Ar), 131.5 (C-3), 141.2 (C-2), 148.7 (C-4), 149.7 (C-6), 158.5 (C-4 
in Ar); MS EI m/z (rel. %) 329 / 327 (3 / 4, M
+
), 311 (11), 309 (17), 135 (38), 121 (100), 78 (9), 77 
(8); HRMS Found 327.0178, calcd. for C13H11Cl2N3O3327.0177. 
6-Chloro-2-(furan-2-yl)-N-(4-methoxybenzyl)-3-nitropyridin-4-amine (10). A mixture of 
compound 9 (141 mg, 0.430 mmol), (PPh3)2PdCl2 (9 mg, 0.01 mmol) and 2-furyl(tributyl)tin (0.15 
mL, 0.47 mmol) in DMF (3 mL) was stirred at ambient temperature for 1 h under N2 and poured 
into water (25 mL). The resulting mixture was extracted with EtOAc (3  20 mL), the combined 
organic extracts were washed with water (40 mL) and brine (30 mL), dried (MgSO4) and 
evaporated in vacuo. The residue dissolved in THF (8 mL) and KF (500 mg) was added. The 
resulting suspension was stirred at ambient temperature for 18 h, and evaporated with small amount 
of silica gel. The product was purified by flash chromatography on silica gel eluting with hexane 
followed by EtOAc-hexane (1:5); yield 120 mg (78%), yellow wax. 
1
H NMR (DMSO-d6, 300 
MHz)  3.72 (s, 3H, OCH3), 4.41 (d, J = 5.9 Hz, 2H, CH2), 6.67 (dd, J = 3.5 and 1.8 Hz, 1H, H-4 in 
furyl), 6.73 (s, 1H, H-5), 6.91 (d, J = 8.7 Hz, 2H, CH in Ar), 7.07 (dd, J = 3.5 and 0.7 Hz, 1H, H-3 
in furyl), 7.25 (d, J = 8.7 Hz, 2H, CH in Ar), 7.85-7.88 (m, 2H, NH and H-5 in furyl); 
13
C NMR 
(DMSO-d6, 75 MHz) 44.6 (CH2), 55.0 (OCH3), 105.1 (C-5), 112.4 (C-4 in furyl), 113.5 (C-3 in 
furyl), 114.0 (CH in Ar), 128.2 (CH in Ar), 129.2 (C-1 in Ar), 130.6 (C-3), 139.9 (C-6), 145.9 (C-5 
in furyl), 148.3 (C-2 in furyl), 148.7 (C-2), 150.9 (C-4), 158.4 (C-4 in Ar); MS EI m/z (rel. %) 359 
(3, M
+
), 330 (6), 135 (6), 122 (11), 121 (100), 77 (5); HRMS Found 359.0673, calcd. for 
C17H14ClN3O4 359.0673.  
6-Chloro-2-(furan-2-yl)-N
4
-(4-methoxybenzyl)pyridine-3,4-diamine (11). A suspension of 
compound 10 (95 mg, 0.29 mmol), K2CO3 (240 mg, 1.74 mmol) and Na2S2O4 (252 mg, 1.45 mmol) 
in MeOH (4.0 mL) and water (0.20 mL) was stirred under N2 at ambient temperature for 12 h 
before the MeOH was removed in vacuo. The residue dissolved in EtOAc (30 mL), washed with 
water (20 mL), dried (MgSO4) and evaporated in vacuo. The product was purified by flash 
chromatography on silica gel eluting with hexane followed by EtOAc-hexane (1:4); yield 80 mg 
(93%), pale yellow wax.
 1
H NMR (DMSO-d6, 300 MHz)  3.73 (s, 3H, CH3), 4.33 (d, J = 5.5 Hz, 
2H, CH2), 5.21 (br s, 2H, NH2), 6.23 (s, 1H, H-5), 6.59-6.61 (m, 2H, H-4 in furyl and NH), 6.81 
(dd, J = 3.4 and 0.7 Hz, 1H, H-3 in furyl), 6.90 (d, J = 8.7 Hz, 2H, Ar), 7.28 (d, J = 8.6 Hz, 2H, Ar), 
7.76 (dd, J = 1.7 and 0.8 Hz, 1H, H-5 in furyl); 
13
C NMR (DMSO-d6, 75 MHz)  45.4 (CH2), 55.0 
(CH3), 101.7 (C-5), 108.6 (C-3 in furyl), 111.5 (C-4 in furyl), 113.8 (CH in Ar), 126.7 (C-6), 128.5 
(CH in Ar), 129.2 (C-2), 130.2 (C-1 in Ar), 139.1 (C-3), 142.2 (C-5 in furyl), 145.1 (C-4), 153.3 (C-
2 in furyl), 158.4 (C-4 in Ar); MS EI m/z (rel. %) 329 (11, M
+
), 330 (6), 180 (2), 122 (10), 121 
(100), 77 (5); HRMS Found 329.0932, calcd. for C17H16ClN3O2 329.0931. 
6-Chloro-4-(furan-2-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridine (12). A solution of 
compound 11 (70 mg, 0.24 mmol) in triethylorthoformate (2 mL) and Ac2O (2 mL) was heated at 
reflux for 2 h under N2 and evaporated in vacuo. The product was purified by flash chromatography 
on silica gel eluting with hexane followed by EtOAc-hexane (3:7); yield 65 mg (79%), mp 155-157 
o
C, pale yellow solid. 
1
H NMR (Me2CO-d6, 300 MHz)  3.77 (s, 3H, CH3), 5.53 (s, 2H, CH2), 6.68 
(dd, J = 3.4 and 1.8 Hz, 1H, H-4 in furyl), 6.93 (d, J = 8.7 Hz, 2H, Ar), 7.36 (d, J = 8.7 Hz, 2H, Ar), 
7.48 (s, 1H, H-7), 7.77 (dd, J = 1.7 and 0.8 Hz, 1H, H-5 in furyl), 7.84 (dd, J = 3.4 and 0.7 Hz, 1H, 
H-3 in furyl), 8.43 (s, 1H, H-2); 
13
C NMR (Me2CO-d6, 75 MHz) 48.9 (CH2), 55.5 (CH3), 105.2 (C-
7), 112.9 (C-4 in furyl), 115.1 (CH in Ar), 115.7 (C-3 in furyl), 128.6 (C-1 in Ar), 130.0 (CH in Ar), 
137.0 (C-3a), 140.8 (C-4), 142.6 (C-7a), 143.3 (C-6), 145.2 (C-5 in furyl), 147.2 (C-2), 151.1 (C-2 
in furyl), 160.7 (C-4 in Ar); MS EI m/z (rel. %) 341 / 339 (17 / 47, M
+
), 122 (13), 121 (100), 78 (8), 
77 (7); HRMS Found 339.0775, calcd. for C18H14ClN3O2339.0775. Anal. Found C, 63.77; H, 4.31; 
N, 12.31. C18H14ClN3O2 requires C, 63.63; H, 4.15; N, 12.37%.  
4-Chloro-1-(4-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (15a). Compound 13a (153 mg, 1.00 
mmol) was dissolved in DMF (4.0 mL) and cooled to 0 
o
C. NaH (ca. 60%, 44 mg, ca. 1.1 mmol) 
was added and reaction mixture was stirred under N2 for 1 h before 4-methoxybenzyl chloride (0.14 
mL, 1.0 mmol) was added. The resulting mixture was stirred for 19 h and evaporated in vacuo. 
Water (40 mL) was added to the residue, which was extracted with EtOAc (2  40 mL). The 
combined organic layers were washed with brine (40 mL), dried (MgSO4) and evaporated in vacuo. 
The product was purified by flash chromatography on silica gel eluting with CH2Cl2 followed by 
MeOH-CH2Cl2 (1:19); yield 235 mg (86%), pale yellow wax.
 1
H NMR (CDCl3, 300 MHz)  3.77 
(s, 3H, OCH3), 5.41 (s, 2H, CH2), 6.55 (d, J = 3.5 Hz, 1H, H-3), 6.82 (d, J = 8.7 Hz, 2H, Ar), 7.09 
(d, J = 5.2 Hz, 1H, H-5), 7.16 (d, J = 8.7 Hz, 2H, Ar), 7.18 (d, J = 3.5 Hz, 1H, H-2), 8.22 (d, J = 5.2 
Hz, 1H, H-6); 
13
C NMR (CDCl3, 75 MHz)  48.3 (CH2), 55.7 (OCH3), 99.1 (C-3), 114.6 (CH in 
Ar), 116.4 (C-5), 120.4 (C-3a), 128.8 (C-1 in Ar), 129.6 (CH in Ar), 129.8 (C-2), 136.7 (C-4), 143.3 
(C-6), 159.7 (C-4 in Ar); MS EI m/z (rel. %) 274 / 272 (14 / 43 M
+
), 122 (10), 121 (100), 78 (5); 
HRMS Found 272.0717, calcd. for C15H13ClN2O 272.0716. 
4-Bromo-6-chloro-1-(4-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (15b). Compound 13b (80 
mg, ca. 0.35 mmol, cont. ca. 0.10 mmol of 6-chloro-1H-pyrrolo[2,3-b]pyridine) was dissolved in 
DMF (3.0 mL) and cooled to 0 
o
C. NaH (ca. 60%, 22 mg, ca. 0.54 mmol) was added and reaction 
mixture was stirred under N2 for 1 h before 4-methoxybenzyl chloride (0.07 mL, 0.5 mmol) was 
added. The reaction mixture was stirred for 1.5 h while reaching ambient temperature and quenched 
by adding few drops of water. The mixture was poured into water (25 mL) and extracted with 
EtOAc (2  30 mL). The combined organic layers were dried (MgSO4) and evaporated in vacuo. 
The product was purified by flash chromatography on silica gel eluting with hexane followed by 
EtOAc-hexane (1:5); yield 101 mg (ca. 82% 15b and 6% 15a), pale yellow wax. 
1
H NMR (CDCl3, 
300 MHz)  3.76 (s, 3H, OCH3), 5.33 (s, 2H, CH2), 6.45 (d, J = 3.5 Hz, 1H, H-3), 6.83 (d, J = 8.6 
Hz, 2H, CH in Ar), 7.11-7.15 (m, 3H, H-2 and CH in Ar), 7.28 (s, 1H, H-5); 
13
C NMR (CDCl3, 75 
MHz)  47.9 (CH2), 55.3 (CH3), 100.5 (C-3), 114.2 (CH in Ar), 118.6 (C-5), 120.6 (C-3a), 126.3 
(C-4), 128.4 (C-2), 128.7 (C-1 in Ar), 129.2 (CH in Ar), 144.3 (C-6), 146.0 (C-7a), 159.4 (C-4 in 
Ar); HRMS Found 349.9827, calcd. for C15H12BrClN2O 349.9822. 
4-Chloro-1-(4-methoxybenzyl)-1H-pyrrolo[3,2-c]pyridine (16a). Compound 14a (125 mg, 0.82 
mmol) was dissolved in DMF (3.0 mL) and cooled to 0 
o
C. NaH (ca. 60%, 43 mg, ca. 1.07 mmol) 
was added and reaction mixture was stirred under N2 for 1 h before 4-methoxybenzyl chloride (0.13 
mL, 0.98 mmol) was added. The reaction mixture was stirred for 1.5 h while reaching ambient 
temperature and quenched by adding few drops of water. The mixture was poured into water (25 
mL) and extracted with EtOAc (2  30 mL). The combined organic layers were dried (MgSO4) and 
evaporated in vacuo. The product was purified by flash chromatography on silica gel eluting with 
hexane followed by CH2Cl2-hexane (1:1); and finally CH2Cl2; yield 165 mg (82%), colorless wax. 
1
H NMR (CDCl3, 300 MHz)  3.76 (s, 3H, OCH3), 5.22 (s, 2H, CH2), 6.65 (d, J = 3.2 Hz, 1H, H-3), 
6.83 (d, J = 8.6 Hz, 2H, Ar), 7.03 (d, J = 8.5 Hz, 2H, Ar), 7.12-7.24 (m, 2H, H-2 and H-7), 8.02 (d, 
J = 5.8 Hz, 1H, H-6); 
13
C NMR (CDCl3, 75 MHz)  50.2 (CH2), 55.3 (OCH3), 101.6 (C-3), 104.9 
(C-7), 114.4 (CH in Ar), 123.8 (C-3a), 127.8 (C-1 in Ar), 128.3 (CH in Ar), 129.5 (C-2), 139.7 (C-
6), 141.0 (C-4), 144.0 (C-7a), 159.5 (C-4 in Ar); MS EI m/z (rel. %) 274 / 272 (7 / 22 M
+
), 122 (10), 
121 (100), 78 (6); HRMS Found 272.0716, calcd. for C15H13ClN2O 272.0716. 
4,6-Dichloro-1-(4-methoxybenzyl)-1H-pyrrolo[3,2-c]pyridine (16b). Compound 14b (200 mg, 
1.07 mmol) was dissolved in DMF (4.0 mL) and cooled to 0 
o
C. NaH (ca. 60%, 56 mg, ca. 1.39 
mmol) was added and reaction mixture was stirred under N2 for 1 h before 4-methoxybenzyl 
chloride (0.16 mL, 1.18 mmol) was added. The reaction mixture was stirred for 1.5 h while 
reaching ambient temperature and quenched by adding few drops of water. The mixture was poured 
into water (25 mL) and extracted with EtOAc (2  30 mL). The combined organic layers were dried 
(MgSO4) and evaporated in vacuo. The product was purified by flash chromatography on silica gel 
eluting with hexane followed by CH2Cl2-hexane (1:1); and finally CH2Cl2; yield 250 mg (75%), 
colorless wax. 
1
H NMR (CDCl3, 300 MHz)  3.78 (s, 3H, CH3), 5.40 (s, 2H, CH2), 6.62 (d, J = 3.3 
Hz, 1H, H-3), 6.86 (d, J = 8.6 Hz, 2H, CH in Ar), 7.03 (d, J = 8.6 Hz, 2H, CH in Ar), 7.12 (d, J = 
3.3 Hz, 1H, H-2), 7.16 (br s, 1H, H-7); 
13
C NMR (CDCl3, 75 MHz)  50.2 (CH2), 55.3 (CH3), 101.7 
(C-3), 104.3 (C-7), 114.5 (CH in Ar), 123.4 (C-3a), 127.3 (C-1 in Ar), 128.4 (CH in Ar), 130.5 (C-
2), 141.0 (C-6), 142.3 (C-7a / C-4), 142.4 (C-7a / C-4), 159.6 (C-4 in Ar); MS EI m/z (rel. %) 308 / 
306 (8 / 12, M
+
), 122 (10), 121 (100), 78 (5); HRMS Found 306.0327, calcd. for C15H12Cl2N2O 
306.0327. 
4-(Furan-2-yl)-1-(4-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (17a). To a mixture of KF (59 
mg, 1.0 mmol) and bis(tri-tert-butylphosphine)palladium(0) (4.8 mg, 5.0 mol) was added a 
solution of compound 15a (85 mg, 0.31 mmol) in dioxane (3 mL) and the mixture was stirred at 
ambient temperature under N2 for 15 min, before furan-2-boronic acid (69 mg, 0.62 mmol) was 
added. The resulting mixture was stirred at reflux under N2 for 2 h before the solvent was 
evaporated in vacuo. The product was purified by flash chromatography on silica gel eluting with 
hexane followed by EtOAc-hexane (2:3); yield 86 mg (90%), pale yellow wax.
 1
H NMR (CDCl3, 
300 MHz)  3.76 (s, 3H, OCH3), 5.48 (s, 2H, CH2), (dd, J = 3.4 and 1.8 Hz 1H, H-4 in furyl), 6.82 
(d, J = 8.7 Hz, 2H, Ar), 6.90 (d, J = 3.5 Hz, 1H, H-3), 7.01 (d, J = 3.4, 1H, H-3 in furyl), 7.19 (d, J 
= 7.6 Hz, 2H, Ar), 7.21 (d, J = 3.5 Hz, 1H, H-3), 7.38 (d, J = 5.2 Hz, 1H, H-5), 7.62 (br d, J = 1.3 
Hz, 1H, H-5 in furyl), 8.34 (d, J = 5.2 Hz, 1H, H-6); 
13
C NMR (CDCl3, 75 MHz)  47.8 (CH2), 
55.25 (OCH3), 100.7 (C-3), 110.4 (C-5), 110.8 (C-3 in furyl), 112.1 (C-4 in furyl), 114.1 (CH in 
Ar), 115.7 (C-3a), 128.5 (C-2), 129.1 (CH in Ar), 129.2 (C-1 in Ar), 141.9 (C-6), 143.7 (C-5 in 
furyl), 152.2 (C-2 in furyl), 159.2 (C-4 in Ar), C-4 and C-7a were hidden; MS EI m/z (rel. %) 304 
(100, M
+
), 303 (38), 289 (13), 197 (10), 121 (99); HRMS Found 304.1209, calcd. for C19H15ClN2O2 
304.1212. Anal. Found C, 74.60; H, 5.35; N, 9.01. C19H15ClN2O2 requires C, 74.98; H, 5.30; N, 
9.20%. 
6-Chloro-4-(furan-2-yl)-1-(4-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (17b). A mixture of 
compound 15b (175 mg, ca. 0.410 mmol, purity see above), (PPh3)2PdCl2 (15 mg, 0.021 mmol) and 
2-furyl(tributyl)tin (0.13 mL, 0.41 mmol) in DMF (3 mL) was stirred under N2 at ambient 
temperature for 40 min and poured into water (20 mL). The resulting mixture was extracted with 
EtOAc (3  20 mL), the combined organic extracts were washed with water (40 mL) and brine (30 
mL), dried (MgSO4) and evaporated in vacuo. The residue was dissolved in THF (8 mL) and KF 
(500 mg) was added. The resulting suspension was stirred at ambient temperature for 18 h, and 
evaporated with small amount of silica gel. The product was purified by flash chromatography on 
silica gel eluting with hexane followed by EtOAc-hexane (1:9) and finally EtOAc-hexane (1:4); 
yield 85 mg (60%), yellow wax. 
1
H NMR (MeCN-d3, 300 MHz)  3.73 (s, 3H, OCH3), 5.34 (s, 2H, 
CH2), 6.63 (dd, J = 3.5 and 1.8 Hz, 1H, H-4 in furyl), 6.85 (d, J = 8.8 Hz, 2H, CH in Ar), 7.16-7.20 
(m, 3H, CH in Ar and H-3 in furyl), 7.40-7.41 (m, 2H, H-2 and H-5 in furyl), 7.73 (dd, J = 1.7 and 
0.5 Hz, H-5 in furyl); 
13
C NMR (MeCN-d3, 75 MHz)  48.2 (CH2), 55.8 (OCH3), 101.2 (C-3), 
110.9 (C-5), 112.2 (C-3 in furyl), 113.3 (C-4 in furyl), 114.6 (C-3a), 114.9 (CH in Ar), 129.7 (CH 
in Ar), 130.3 (C-2), 130.8 (C-1 in Ar), 133.1 (C-4), 145.3 (C-6), 145.4 (C-5 in furyl), 148.4 (C-7a), 
151.9 (C-2 in furyl), 160.2 (C-4 in Ar); MS EI m/z (rel. %) 340 / 338 (18 / 51, M
+
), 122 (11), 121 
(100), 91 (3), 77 (4); HRMS Found 338.0822, calcd. for C19H15ClN2O2 338.0822. Anal. Found C, 
67.66; H, 4.55; N, 8.20. C19H15ClN2O2 requires C, 67.36; H, 4.46; N, 8.27%.  
4-(Furan-2-yl)-1-(4-methoxybenzyl)-1H-pyrrolo[3,2-c]pyridine (18a). A mixture of compound 
16a (100 mg, 0.37 mmol) and Pd(Pt-Bu)2 (6.0 mg, 0.011 mmol) in DMF (3 mL) was stirred at 
ambient temperature under N2 for 5 min before 2-furyl(tributyl)tin (0.16 mL, 0.52 mmol) was 
added. The resulting mixture was stirred at 85 
o
C for 20 h. DMF was removed in vacuo, the residue 
was dissolved in THF (4 mL) and KF (ca. 0.2 g) was added. The resulting suspension was stirred at 
ambient temperature for 24 h and evaporated with small amount of silica gel. The product was 
purified by flash chromatography on silica gel eluting with hexane, followed by EtOAc-hexane 
(1:4) and finally EtOAc-hexane (1:1); yield 82 mg, (73%), pale yellow wax. 
1
H NMR (MeCN-d6, 
300 MHz)  3.73 (s, 3H, OCH3), 5.31 (s, 2H, CH2), 6.62 (dd, J = 3.3 and 1.8 Hz, 1H, H-4 in furyl), 
6.85 (d, J = 8.7 Hz, 2H, CH in Ar), 7.11-7.16 (m, 4H, H-3, CH in Ar and H-3 in furyl), 7.28 (d, J = 
5.7 Hz, 1H, H-7), 7.40 (d, J = 3.3 Hz, 1H, H-2), 7.70 (br s, 1H, H-5 in furyl), 8.20 (d, J = 5.7 Hz, 
1H, H-6), 
13
C NMR (MeCN-d6, 75 MHz)  50.0 (CH2), 55.8 (OCH3), 102.7 (C-3), 105.3 (C-7), 
110.1 (C-3 in furyl), 112.7 (C-4 in furyl), 115.0 (CH in Ar), 121.5 (C-3a), 129.5 (CH in Ar), 130.3 
(C-1 in Ar), 131.1 (C-2), 141.1 (C-6), 141.8 (C-7a), 143.0 (C-4), 144.4 (C-5 in furyl), 156.2 (C-2 in 
furyl), 160.2 (C-4 in Ar); MS EI m/z (rel. %) 304 (56 M
+
), 122 (10), 121 (100), 78 (5); HRMS 
Found 304.1212, calcd. for C19H16N2O2 304.1212. Anal. Found C, 74.75; H, 5.16; N, 9.21. 
C19H16N2O2 requires C, 74.98; H, 5.30; N, 9.20%. 
6-Chloro-4-(furan-2-yl)-1-(4-methoxybenzyl)-1H-pyrrolo[3,2-c]pyridine (18b). A mixture of 
compound 16b (150 mg, 0.49 mmol), (PPh3)2PdCl2 (18 mg, 0.025 mmol) and 2-furyl(tributyl)tin 
(0.170 mL, 0.54 mmol) in DMF (3 mL) was stirred under N2 at 60 
o
C for 18 h and poured into 
water (20 mL). The resulting mixture was extracted with EtOAc (3  30 mL) and the combined 
organic extracts were washed with water (40 mL) and brine (30 mL), dried (MgSO4) and 
evaporated in vacuo. The residue was dissolved in THF (8 mL) and KF (ca. 200 mg) was added. 
The resulting suspension was stirred at ambient temperature for 18 h, and evaporated with small 
amount of silica gel. The product was purified by flash chromatography on silica gel eluting with 
hexane followed by CH2Cl2-hexane (3:7); yield 70 mg (43%), yellow wax. 
1
H NMR (Me2CO-d6, 
600 MHz)  3.74 (s, 3H, CH3), 5.40 (s, 2H, CH2), 6.65 (dd, J = 3.4 and 1.8 Hz, 1H, H-4 in furyl), 
6.78 (d, J = 8.7 Hz, 2H, Ar), 7.14 (dd, J = 3.2 and 0.7 Hz, 1H, H-3), 7.21-7.23 (m, 3H, CH in Ar 
and H-3 in furyl), 7.41 (d, J = 0.7 Hz, 1H, H-7), 7.53 (d, J = 3.2 Hz, 1H, H-2), 7.80-7.81 (m, 1H, H-
5 in furyl); 
13
C NMR (Me2CO-d6, 150 MHz)  50.0 (CH2), 55.5 (CH3), 103.0 (C-3), 104.3 (C-7), 
111.3 (C-3 in furyl), 112.6 (C-4 in furyl), 114.9 (CH in Ar), 120.9 (C-3a), 129.5 (CH in Ar), 129.8 
(C-1 in Ar), 132.4 (C-2), 142.1 (C-4), 142.9 (C-6), 144.0 (C-7a), 145.0 (C-5 in furyl), 155.1 (C-2 in 
furyl), 160.3 (C-4 in Ar); MS EI m/z (rel. %) 340 / 338 (10 / 33, M
+
), 122 (7), 121 (100), 78 (3); 
HRMS Found 338.0822, calcd. for C19H15ClN2O2 338.0822. Anal. Found C, 67.35; H, 4.67; N, 
8.56. C19H15ClN2O2 requires C, 67.36; H, 4.46; N, 8.27%. 
3-Bromo-N
1
-(4-methoxybenzyl)benzene-1,2-diamine (20). Compound 19 (338 mg, 1.00 mmol) 
was suspended in MeOH (10 mL) and K2CO3 (829 mg, 6.00 mmol) were added followed by 
Na2S2O4 (871 mg, 5.00 mmol) and water (0.3 mL). The resulting suspension was stirred under N2 
for 36 h, additional Na2S2O4 (871 mg, 5.00 mmol) was added and the reaction mixture was stirred 
for further 12 h. The mixture was evaporated in vacuo and the residue was partitioned between 
water (40 mL) and EtOAc (40 mL). The phases were separated and the aq. phase was re-extracted 
with EtOAc (40 mL). The combined organic layers were washed with brine (40 mL), dried 
(MgSO4) and evaporated in vacuo. The product was purified by flash chromatography on silica gel 
eluting with hexane, followed by EtOAc-hexane (1:9); yield 230 mg (75%), pale yellow oil. 
1
H 
NMR (DMSO-d6, 300 MHz)  3.71 (s, 3H, CH3), 4.21 (d, J = 5.7 Hz, 2H, CH2), 4.73 (s, 2H, NH2), 
7.73 (t, J = 5.6 Hz, 1H, NH), 6.33-6.36 (m, 2H, H-5 and H-6), 6.66 (dd, J = 6.7 and 2.6 Hz, 1H, H-
4), 6.86 (d, J = 8.7 Hz, 2H, CH in Ar), 7.26 (d, J = 8.7 Hz, 2H, CH in Ar); 
13
C NMR (DMSO-d6, 75 
MHz)  46.4 (CH2), 55.0 (CH3), 108.1 (C-3), 109.2 (C-6), 113.66 (CH in Ar), 118.2 (C-5), 119.7 
(C-4), 128.4 (CH in Ar), 131.6 (C-1 in Ar), 132.3 (C-2), 136.6 (C-1), 158.1 (C-4 in Ar); MS EI m/z 
(rel. %) 308 / 306 (15 / 16, M
+
), 122 (17), 121 (100), 91 (5), 78 (9), 77 (7); HRMS Found 306.0358, 
calcd. for C14H15BrN2O 306.0368.  
4-Bromo-1-(4-methoxybenzyl)-1H-benzo[d]imidazole (21). p-Toluenesulfonic acid monohydrate 
(11 mg, 0.059 mmol) was added to a solution of 20 (120 mg, 0.390 mmol) in triethylorthoformate 
(4.5 mL) and the resulting mixture was heated at reflux under N2 for 2 h and excess of 
triethylorthoformate was removed in vacuo. The product was purified by flash chromatography on 
silica gel eluting with hexane followed by EtOAc-hexane (3:1); yield 110 mg (90%), colorless wax. 
1
H NMR (CDCl3, 300 MHz)  3.76 (s, 3H, OCH3), 5.26 (s, 2H, CH2), 6.84 (d, J = 8.7 Hz, 2H, CH 
in Ar), 7.05-7.11 (m, 3H, H-6 and CH in Ar), 7.20-7.24 (m, 1H, H-7), 7.44 (dd, J = 7.7 and 0.9 Hz, 
1H, H-5), 7.96 (s, 1H, H-2); 
13
C NMR (CDCl3, 75 MHz)  48.8 (CH2), 55.3 (OCH3), 109.5 (C-7), 
113.9 (C-4), 114.5 (CH in Ar), 124.0 (C-6), 125.3 (C-5), 126.8 (C-1 in Ar), 128.6 (CH in Ar), 134.4 
(C-7a), 142.7 (C-3a), 143.4 (C-2), 159.7 (C-4 in Ar); MS EI m/z (rel. %) 318 / 316 (12 / 13, M
+
), 
122 (9), 121 (100), 78 (6), 77 (5); HRMS Found 316.0203, cacld. for  C15H13BrN2O 316.0211.  
4-(Furan-2-yl)-1-(4-methoxybenzyl)-1H-benzo[d]imidazole (22). A mixture of compound 21, (90 
mg, 0.25 mmol) and Pd(Pt-Bu)2 (7.0 mg, 0.013 mmol) in DMF (3 mL) was stirred ambient 
temperature under N2 for 5 min before 2-furyl(tributyl)tin (0.1 mL, 0.3 mmol) was added. The 
resulting mixture was stirred at 85 
o
C for 2 h. DMF was removed in vacuo, the residue was 
dissolved in THF (4mL) and KF (ca. 0.2 g) was added. The resulting suspension was stirred at 
ambient temperature for 24 h and evaporated with small amount of silica gel. The product was 
purified by flash chromatography on silica gel eluting with hexane, followed by EtOAc-hexane 
(1:4) and finally EtOAc-hexane (2:3); yield 58 mg (76%), mp 99-100 
o
C, pale yellow crystals. 
1
H 
NMR (CDCl3, 300 MHz)  3.76 (s, 3H, OCH3), 5.29 (s, 2H, CH2), 6.56 (dd, J = 3.3 and 1.8 Hz, 1H, 
H-4 in furyl), 6.84 (d, J = 8.7 Hz, 2H, Ar), 7.11 (d, J = 8.8 Hz, 2H, Ar), 7.18 (dd, J = 8.0 and 1.1 
Hz, 1H, H-6), 7.24-7.28 (m, 1H, H-7), 7.50-7.52 (m, 2H, H-3 and H-5 in furyl), 7.69 (dd, J = 7.4 
and 1.1 Hz, 1H, H-5), 7.97 (s, 1H, H-2); 
13
C NMR (CDCl3, 75 MHz)  48.5 (CH2), 55.3 (OCH3), 
109.0 (C-6), 110.1 (C-3 in furyl), 111.9 (C-4 in furyl), 114.4 (CH in Ar), 117.7 (C-5), 122.6 (C-6 / 
C-7), 123.1 (C-6 / C-7), 127.4 (C-1 in Ar), 128.5 (CH in Ar), 134.5 (C-7a), 139.5 (C-3a), 141.8 (C-
5 in furyl), 142.9 (C-2), 151.4 (C-2 in furyl), 159.5 (C-4 in Ar); MS EI m/z (rel. %) 304 (67, M
+
), 
122 (12), 121 (100), 78 (5), 77 (6); HRMS Found 304.1202, calcd. for C19H16N2O2 304.1212. Anal. 
Found C, 74.99; H, 5.47; N, 9.27. C19H16N2O2 requires C, 74.98; H, 5.30; N, 9.20%. 
4-Bromo-1-(4-methoxybenzyl)-1H-indole (24a) and 4-bromo-1,3-di(4-methoxybenzyl)-1H-
indole (24b). 4-Bromoindole (23) (0.38 mL, 3.0 mmol) was added drop wise to a stirring mixture 
of K2CO3 (1.24 g, 9.00 mmol) in DMF (12 mL) under N2 at ambient temperature. The resulting 
mixture was stirred for 1 h, before 4-methoxybenzyl chloride (0.81 mL, 6.0 mmol) was added drop 
wise. The reaction mixture was stirred for 18 h, filtered and evaporated in vacuo. The products were 
separated by flash chromatography on silica gel eluting with EtOAc-hexane (1:20) followed by 
EtOAc-hexane (1:10).   
24a: Yield 242 mg (26%), colorless oil. 
1
H NMR (CDCl3, 200 MHz)  3.75 (s, 3H, OCH3), 5.21 (s, 
2H, CH2), 6.57 (d, J = 3.0 Hz, 1H, H-3), 6.81 (d, J = 8.6 Hz, 2H, Ar), 6.96-7.05 (m, 3H, Ar and 
indole), 7.14 (d, J = 3.0 Hz, H-2), 7.20-2.28 (m, 2H, indole); 
13
C NMR (CDCl3, 50 MHz)  49.7 
(CH2), 55.3 (CH3), 101.9 (C-3), 108.9 (C-7), 114.1 (CH in Ar), 114.8 (C-4), 122.3 (C-5 / C-6), 
122.4 (C-5 / C-6), 128.1 (CH in Ar), 128.6 (C-2), 128.8 (C-1 in Ar), 129.3 (C-3a), 136.4 (C-7a), 
159.1 (C-4 in Ar); MS EI m/z (rel. %) 317 / 315 (26 / 27, M
+
), 228 (7), 197 (7), 122 (13), 121 (100), 
115 (19); HRMS Found 315.0268, calcd. for C16H14BrNO 3150259. 
24b: Yield 344 mg (26%), colorless oil. 
1
H NMR (CDCl3, 200 MHz)  3.77 (s, 3H, OCH3), 3.80 (s, 
3H, OCH3), 4.40 (s, 2H, CH2), 5.13 (s, 2H, CH2), 6.72 (s, 1H, H-2), 6.80-6.93 (m, 4H), 6.98-7.03 
(m, 3H), 7.17-2.28 (m, 4H); 
13
C NMR (CDCl3, 50 MHz)  31.5 (CH2), 49.5 (CH2), 55.2 (2  CH3), 
109.0 (C-7), 113.6 (CH in Ar), 114.0 (CH in Ar), 114.5 (C-3 / C-4), 116.1 (C-3 / C-4), 122.4 (C-5 / 
C-6), 123.5 (C-5 / C-6), 126.0 (C-3a), 127.8 (CH in Ar), 128.5 (C-2), 129.0 (C-1 in Ar), 129.7 (CH 
in Ar), 133.6 (C-1 in Ar), 137.8 (C-7a), 157.6 (C-4 in Ar), 159.0 (C-4 in Ar); MS EI m/z (rel. %) 
437 / 435 (15 / 15, M
+
), 355 (1), 316 (2), 315 (1), 235 (3), 234 (2), 192 (2), 191 (4), 190 2) 122 (9), 
121 (100); HRMS Found 435.0813, calcd. for C24H22BrNO2 435.0834. 
4-(Furan-2-yl)-1-(4-methoxybenzyl)-1H-indole (25). A mixture of 24a (190 mg, 0.600 mmol), 2-
furyl(tributyl)tin (0.28 mL, 0.90 mmol) and (Ph3P)2PdCl2 (22 mg. 0.030 mmol) in DMF (5 mL) was 
stirred at 90 
o
C under N2 for 17 h, and evaporated in vacuo. KF in MeOH (sat. sol., 10 mL) was 
added to the residue and the resulting mixture was stirred for 18 h. The product was purified by 
flash chromatography on silica gel eluting with EtOAc-hexane (1:10); yield 138 mg (76%), pale 
yellow oil. 
1
H NMR (CDCl3, 200 MHz)  3.76 (s, 3H, OCH3), 5.27 (s, 2H, CH2), 6.53 (m, 1H, 
furyl), 6.79-6-84 (m, 3H, H-3 and Ar), 6.98 (d, J = 3.2 Hz, 1H), 7.06 (d, J = 8.4 Hz, 2H, Ar), 7.17-
7.21 (m, 3H), 7.48 (m, 1H), 7.54 (br s, 1H); 
13
C NMR (CDCl3, 50 MHz)  49.6 (CH2), 55.1 (CH3), 
101.5 (C-3), 106.3 (C-7 / CH in furyl), 109.1 (C-7 / CH in furyl), 111.4 (C-7 / CH in furyl), 116.2 
(C-5 / C-6), 121.6 (C-5 / C-6), 123.1 (C-3a / C-4), 124.2 (C-3a / C-4), 128.0 (CH in Ar), 128.6 (C-
2), 129.2 (C-1 in Ar), 136.8 (C-7a), 141.5 (CH in furyl), 154.4 (C in furyl), 158.9 (C-4 in Ar); MS 
EI m/z (rel. %) 303 (100, M
+
), 183 (6), 182 (6), 155 (4), 154 (5), 153 (3), 127 (6), 126 (3), 122 (10), 
121 (100), 78 (6), 77 (6); HRMS Found 303.1252, calcd. for C20H17NO2 303.1259. 
Determination of activity against S. aureus and E. coli. The antimicrobial susceptibilities of the 
quality control (QC) strains S. aureus (ATCC 29213) and E. coli (ATCC 25922) to test 
antimicrobials were determined by the broth microdilution method using cation-adjusted Mueller-
Hinton broth (Oxoid, UK) essentially as previously described.
14
 In brief, serial twofold dilutions (16 
– 0.125 µg/mL) of all samples were prepared in triplicate in microtiter plates and inoculated with a 
suitably prepared cell suspension to achieve the required start concentration. DMSO was used as 
solvent and diluent for the test substances, whereas the gentamicin control (used to control the 
accuracy of testing) was prepared using water as solvent and broth as diluent.  Dilution schemes, 
preparation of the inoculum and incubation conditions were as described in the standard method and 
in the performance standards supplement.
13,14
 For both test substances and gentamicin the lowest 
concentration that completely inhibited microbial growth as detected by the unaided eyes was taken 
as the substance MIC value 
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Legends to Figures and Schemes 
 
Fig. 1. Structures of some of the most active purines and deazapurines 1 as well the general 
structure of the target compounds described in this study. 
 
Scheme 1. (a) p-MeO-C6H4-CH2NH2, Et3N, n-BuOH (DMF as solvent for 3b); (b) Na2S2O4, 
K2CO3, MeOH, H2O, for 4a; (c) Raney Ni, NaBH4, MeOH for 4b; (d) CH(OEt3), Ac2O, . 
 
Scheme 2. (a) (2-Furyl)SnBu3, Pd(dppf)Cl2, DMF, 90 
o
C. 
 
Scheme 3. (a) NaH, NaI, p-MeO-C6H4-CH2Cl, THF, 0 
o
C – r.t.; (b) (2-Furyl)SnBu3, (Ph3P)2PdCl2, 
DMF; (c) Na2S2O4, K2CO3, MeOH, H2O; (d) CH(OEt)3, Ac2O, . 
 
Scheme 4. (a) NaH, p-MeO-C6H4-CH2Cl, DMF; (b) (2-Furyl)B(OH)2, [(t-Bu)3P]2Pd, KF, dioxane, 
 for 17a; (c) (2-Furyl)SnBu3, (Ph3P)2PdCl2, DMF, for 17b (r.t.) and 18b (60 
o
C); (d) (2-
Furyl)SnBu3, (t-Bu3P)2Pd, DMF, 85 
o
C, for 18a. 
 
Scheme 5. (a) Na2S2O4, K2CO3, MeOH, H2O; (b) CH(OEt)3, p-TSA, ; (c) (2-Furyl)SnBu3, [(t-
Bu)3P]2Pd, DMF, 85 
o
C. 
 
Scheme 6. (a) K2CO3, p-MeO-C6H4-CH2Cl, DMF; (b) (2-Furyl)SnBu3, (Ph3P)2PdCl2, DMF, 90 
o
C. 
Table. Antibacterial activity against M. tuberculosis, and cytotoxic activity against VERO cells for 
compounds 5a, 5b, 7, 12, 17a, 17b, 18a, 18b, 22 and 25. 
Comp. 
No. 
X
a 
A
a 
B
a 
C
a 
MIC (MABA) M. 
tuberculosis 
H37Rv (M) 
[inhib. at 128 
(M)]b 
MIC (LORA) M. 
tuberculosis 
H37Rv pFPCA-
luxAB (M)c 
IC50 VERO 
cells (M) 
[inhib. at 
128 (M)]d 
SI 
(EC50:MIC) 
5a  H CH N N 63 n.d.
e 
n.d. n.d. 
5b  Cl CH N N >128 [37%] n.d. n.d. n.d. 
7   H N CH N 0.84 80 >128 [0%] >150 
12  Cl N CH N 0.16 48 >128 
[30%] 
>800 
17a  H CH N CH 44 n.d. n.d. n.d. 
17b  Cl CH N CH >128 [86%] n.d. n.d. n.d. 
18a H N CH CH 1.40 28 12 8.6 
18b Cl N CH CH 0.090 >128 [53%] 58 644 
22  H CH CH N 29 n.d. n.d. n.d. 
25  H CH CH CH >21 [0% at 21 
M]  
n.d. n.d. n.d. 
(a) See Fig. 1; (b) MIC rifampicin 0.09 M, MIC isoniazid 0.28 M, MIC PA-824 0.44 M; (c) 
MIC rifampicin 0.97 M, MIC isoniazid >128 M, MIC PA-824 3.11 M; (d) EC50 hyamine 0.01 
g/mL (ca. 0.03 M); (e) Not determined. 
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